Panacea Life Sciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLSH research report →
Price Chart
About the company
Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale. Its core mission is to develop and deliver natural, pharmaceutical-grade alternatives for both human and pet consumption.
- CEO
- Leslie A. Buttorff
- IPO
- 2022
- Employees
- 3
- HQ
- Greenwood Village, CO, US
Get TickerSpark's AI analysis on PLSH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.75M
- P/E
- -0.81
- PEG
- 0.01
- P/S
- 6.63
- P/B
- 4.46
- EV/EBITDA
- -0.71
- Div Yield
- 0.00%
- Gross Margin
- -612.89%
- Op Margin
- -289.21%
- Net Margin
- -2147.67%
- ROE
- -145.76%
- ROIC
- -59.37%
Latest fiscal year · YoY change
- Revenue
- $910.52K-77.8%
- Gross Profit
- $-1,219,562-142.8%
- Op Income
- $-1,753,336
- Net Income
- $-416,675+28.6%
- EPS
- $-0.01+77.8%
- OCF Growth
- -10.4%
- FCF Growth
- -10.4%
- 52W High
- $0.20
- 52W Low
- $0.02
- 50D MA
- $0.08
- 200D MA
- $0.05
- Beta
- 2.54
- RSI (14)
- 47
- Avg Volume
- 19.41K
No earnings-call transcripts are available for PLSH yet.
- Free Float
- 47.7%
- Shares Outstanding
- 21.22M
- Float Shares
- 10.13M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 23 | Buttorff Leslie | buy | 20,000 |
| Jun 9, 23 | Buttorff Leslie | buy | 3,000 |
| Jun 2, 23 | Buttorff Leslie | other | 760,000 |
| May 23, 23 | Buttorff Leslie | buy | 500 |
| May 19, 23 | Buttorff Leslie | buy | 1,500 |
| May 19, 23 | Buttorff Leslie | buy | 4,500 |
| May 9, 23 | Buttorff Leslie | buy | 2,300 |
| May 8, 23 | Buttorff Leslie | buy | 1,500 |
| May 5, 23 | Buttorff Leslie | buy | 11,500 |
| Apr 26, 23 | Buttorff Leslie | buy | 5,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLSH coverage
Recent articles, reports, and earnings notes.
No research on PLSH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLSH report →Panacea Life Sciences Holdings (OTCID: PLSH) and Benivita Inc. Launch Benivita PLSH -- a New Era in Direct-to-Consumer Virtual Benefits
prnewswire.com · Nov 18
Panacea Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products
globenewswire.com · May 16
Panacea Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution Center Locations in the Tampa, Florida area
globenewswire.com · Oct 5
Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
globenewswire.com · Oct 2
Panacea Life Sciences Holdings, Inc. Celebrates National CBD Day (August 8th) By Shifting To An “Everyday Low Pricing Model” To Meet Customer Needs
globenewswire.com · Aug 8
Panacea Life Sciences Holdings, Inc. Continues Pursuit of High Growth Health and Wellness Products with Acquisition of Sierra Sage, LLC and Halucenex from Melodial Global Health (formerly Creso Pharma Limited)
globenewswire.com · Aug 2
Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
globenewswire.com · Jul 20
Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast
accesswire.com · Jul 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.